Potential CD34 signaling through phosphorylated-BAD in chemotherapy-resistant acute myeloid leukemia

References

• Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Brenner AK, Hagen KM, et al. The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Res. 2015;15:530–541.
   PubMed Web of Science ®Google Scholar
• Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev. 2018;43:8.
   PubMed Web of Science ®Google Scholar
• Nielsen JS, McNagny KM. Novel functions of the CD34 family. J Cell Sci. 2008;121:36833–36892.
   Web of Science ®Google Scholar
• AbuSamra DB, Aleisa FA, Al-Amoodi AS, et al. Not just a marker: CD34 on human hematopoietic stem/progenitor cells dominates vascular selectin binding along with CD44. Blood Adv. 2017;1(27):2799.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991;78:2962–2968.
   PubMed Web of Science ®Google Scholar
• Cascavilla N, Musto P, D’Arena G, et al. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype. Haematologica. 1998;83:392–397.
   PubMed Web of Science ®Google Scholar
• Foster B, Zaidi D, Young T, et al. CD117/c-kit in cancer stem cell-mediated progression and therapeutic resistance. Biomedicines. 2018;6(1):31.
   PubMed Web of Science ®Google Scholar
• Heo SK, Noh EK, Kim JY, et al. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Sci Rep. 2017;7(1):15278.
   PubMedGoogle Scholar
• Berenstein R. Class III receptor tyrosine kinases in acute leukemia – biological functions and modern laboratory analysis. Biomark Insights. 2015;10s3:BMI.S22433.
   Google Scholar
• Guenova ML, Balatzenko GN, Nikolova VR, et al. An anti-apoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase-3, cleaved PARPs, Bcl-2, Survivin and MDR1 gene. Hematology. 2010;15(3):135.
   PubMed Web of Science ®Google Scholar
• Evangelisti C, Evangelisti C, Bressanin D, et al. Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. Expert Opin Ther Targets. 2013;17:921–936.
   PubMed Web of Science ®Google Scholar
• McLornan DP, McMullin MF, Johnston P, et al. Molecular mechanisms of drug resistance in acute myeloid leukaemia. Expert Opin Drug Metab Toxicol. 2007;3:363–377.
   PubMed Web of Science ®Google Scholar
• Udelnow A, Schönfeldȩr M, Würl P, et al. In vitro chemo-sensitivity assay guided chemotherapy is associated with prolonged overall survival in cancer patients. Pol Prz Chir Polish J Surg. 2013;85:340–347.
   PubMedGoogle Scholar
• Yu T, Lin J, Zhao J, et al. A simple in vitro tumor chemosensitivity assay based on cell penetrating peptide tagged luciferase. PLOS One. 2017;12(11):e0186184.
   PubMed Web of Science ®Google Scholar
• Selby PJ, Raghavan D. Role of laboratory chemosensitivity testing in the selection of cancer chemotherapy for individual patients. J Clin Pathol. 1981;34:455–463.
   PubMed Web of Science ®Google Scholar
• Ferriss JS, Rice LW. The role of in vitro directed chemotherapy in epithelial ovarian cancer. Rev Obstet Gynecol. 2010;3:49–54.
   PubMedGoogle Scholar
• Arellano M, Pakkala S, Langston A, et al. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. Cancer. 2012;118(21):5278.
   PubMed Web of Science ®Google Scholar
• Øyan AM, Ånensen N, Bø TH, et al. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer. 2009;9(1):77.
   PubMedGoogle Scholar
• Andreeff M, Jiang S, Zhang X, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881–1892.
   PubMed Web of Science ®Google Scholar
• Marchion DC, Cottrill HM, Xiong Y, et al. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011;17:6356–6366.
   PubMed Web of Science ®Google Scholar
• Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000;60:5988–5994.
   PubMed Web of Science ®Google Scholar
• Sastry KSR, Al-Muftah MA, Li P, et al. Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells. Cell Death Differ. 2014;21(12):1936.
   PubMed Web of Science ®Google Scholar
• Maha A, Cheong SK, Leong CF, et al. Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy. Malays J Pathol. 2009;31:81–91.
   PubMedGoogle Scholar
• Harada H, Becknell B, Wilm M, et al. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell. 1999;3:413–422.
   PubMed Web of Science ®Google Scholar
• Datta SR, Ranger AM, Lin MZ, et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell. 2002;3:631–643.
   PubMed Web of Science ®Google Scholar
• Chuang JY, Huang YL, Yen WL, et al. Syk/JNK/AP-1 signaling pathway mediates interleukin-6-promoted cell migration in oral squamous cell carcinoma. Int J Mol Sci. 2014;15:545–559.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Nakamura N, Chauhan D, et al. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20(42):5991.
   PubMed Web of Science ®Google Scholar
• Ham IH, Oh HJ, Jin H, et al. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Mol Cancer. 2019;18(1):68.
   PubMedGoogle Scholar
• Shintani Y, Fujiwara A, Kimura T, et al. IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling. J Thorac Oncol. 2016;11:1482–1492.
   PubMed Web of Science ®Google Scholar
• Lentzsch S, Chatterjee M, Gries M, et al. P13-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia. 2004;18(11):1883.
   PubMed Web of Science ®Google Scholar
• Edfors F, Danielsson F, Hallström BM, et al. Gene‐specific correlation of RNA and protein levels in human cells and tissues. Mol Syst Biol. 2016;12(10):883.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xing D, Liu L, et al. TNFα induces apoptosis through JNK/Bax-dependent pathway in differentiated, but not naïve PC12 cells. Cell Cycle. 2007;6(12):1478.
   Web of Science ®Google Scholar
• Ko C-Y, Wang W-L, Li C-F, et al. IL-18-induced interaction between IMP3 and HuR contributes to COX-2 mRNA stabilization in acute myeloid leukemia. J Leukoc Biol. 2016;99:131–141.
   PubMed Web of Science ®Google Scholar
• Yao L, Zhang Y, Chen K, et al. Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLOS One. 2011;6(9):e24684.
   PubMed Web of Science ®Google Scholar
• Huang CY, Chang WS, Tsai CW, et al. Interleukin-18 promoter genotype is associated with the risk of nasopharyngeal carcinoma in Taiwan. Cancer Manag Res. 2018;31:5199–5207.
   Google Scholar
• Lian H, Jin N, Li X, et al. Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and Apoptin. Cancer Immunol Immunother. 2007;56:181–192.
   PubMed Web of Science ®Google Scholar
• Kang M-J, Homer RJ, Gallo A, et al. IL-18 is induced and IL-18 receptor plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammation. J Immunol. 2007;178:1948–1959.
   PubMed Web of Science ®Google Scholar
• Malaise M, Steinbach D, Corbacioglu S. Clinical implications of c-kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep.. 2009;4(2):77.
   PubMedGoogle Scholar